These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31123759)

  • 1. Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
    van Dyk M; Miners JO; Marshall JC; Wood LS; Hopkins A; Sorich MJ; Rowland A
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1211-1218. PubMed ID: 31123759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.
    van Dyk M; Marshall JC; Sorich MJ; Wood LS; Rowland A
    Eur J Clin Pharmacol; 2018 Jul; 74(7):913-920. PubMed ID: 29572563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
    Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
    Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
    Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate.
    van Dyk M; Kapetas AJ; Hopkins AM; Rodrigues AD; Vourvahis M; Sorich MJ; Rowland A
    Front Pharmacol; 2019; 10():1120. PubMed ID: 31611799
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.
    Shin KH; Choi MH; Lim KS; Yu KS; Jang IJ; Cho JY
    Clin Pharmacol Ther; 2013 Nov; 94(5):601-9. PubMed ID: 23784264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.
    Masters JC; Harano DM; Greenberg HE; Tsunoda SM; Jang IJ; Ma JD
    Ther Drug Monit; 2015 Feb; 37(1):84-9. PubMed ID: 25004135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
    Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
    Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
    Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
    Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
    Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
    Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.
    Rowland A; Ruanglertboon W; van Dyk M; Wijayakumara D; Wood LS; Meech R; Mackenzie PI; Rodrigues AD; Marshall JC; Sorich MJ
    Br J Clin Pharmacol; 2019 Jan; 85(1):216-226. PubMed ID: 30340248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
    Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
    Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
    Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
    Toda A; Uehara S; Inoue T; Utoh M; Kusama T; Shimizu M; Uno Y; Mogi M; Sasaki E; Yamazaki H
    Xenobiotica; 2018 Jul; 48(7):720-726. PubMed ID: 28686070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.